CERO (CERo Therapeutics Holdings) Tariff Resilience Score: 6/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CERo Therapeutics Holdings Tariff Resilience Score?

CERo Therapeutics Holdings CERO -12.75% Tariff Resilience Score is 6 as of Jul. 14, 2026. The stock has 2 warning signs investors should review. Among 1,370 Biotechnology companies, CERo Therapeutics Holdings ranks better than 75.99% on this metric.

CERo Therapeutics Holdings has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

CERo Therapeutics Holdings has CERo Therapeutics Holdings Inc has moderate exposure to tariffs, primarily through imported raw materials for pharmaceuticals. The company can mitigate some risks through alternative suppliers and has some pricing power in niche markets.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CERo Therapeutics Holdings might have Average Resilient.

CERo Therapeutics Holdings  (OTCPK:CERO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CERo Therapeutics Holdings Tariff Resilience Score Related Terms

CERO vs WINT, LIPO, RMTG: Tariff Resilience Score Comparison

For the Biotechnology subindustry, CERo Therapeutics Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
CERo Therapeutics Holdings (CERO) has a Tariff Resilience Score of 6 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CERo Therapeutics Holdings ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is CERo Therapeutics Holdings' Tariff Resilience Score too high?
CERo Therapeutics Holdings' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. CERo Therapeutics Holdings' value of 6 is 50% above this industry median. Based on the distribution chart, CERo Therapeutics Holdings ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CERo Therapeutics Holdings' Tariff Resilience Score compare to WINT and LIPO?
According to the Biotechnology industry distribution chart, CERo Therapeutics Holdings ranks #329 out of 1370 companies for Tariff Resilience Score. This places CERo Therapeutics Holdings in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. CERo Therapeutics Holdings' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CERo Therapeutics Holdings's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CERo Therapeutics Holdings's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current Tariff Resilience Score is 6 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CERo Therapeutics Holdings Business Description

Address 201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.